Phase II trial of pegylated liposomal doxorubicin (PLD), rituxan, cyclophosphamide, vincristine, and prednisone in aggressive B-cell non-Hodgkin's lymphoma

H. Gu,Anil Tulpule,N. Berman,Christine Duran,Susan Groshen,Laura H. Buchanan,William D. Boswell,Bharat N. Nathwani,A. M. Levine

Phase II trial of pegylated liposomal doxorubicin (PLD), rituxan, cyclophosphamide, vincristine, and prednisone in aggressive B-cell non-Hodgkin's lymphoma

2008

H. Gu
Anil Tulpule
N. Berman
Christine Duran
Susan Groshen
Laura H. Buchanan
William D. Boswell
Bharat N. Nathwani
A. M. Levine

8563 Background: The R-CHOP regimen has become the standard of care for treatment of patients with aggressive B-cell lymphomas. Pegylated liposomal doxorubicin (PLD) has an improved pharmacokinetic...

Keywords:

Pegylated Liposomal Doxorubicin
Non-Hodgkin's lymphoma
Pathology
Prednisone
Cancer research
Cyclophosphamide/vincristine
Medicine
B cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations